DALY II USA/ MB-CART2019.1 for DLBCL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie chłoniaka B-komórkowego (różne typy)
- •Chłoniak rozległy dużokomórkowy B-komórkowy (DLBCL) po co najmniej 2 poprzednich leczeniach
- •Chłoniak ośrodkowego układu nerwowego po co najmniej 1 poprzednim leczeniu
- •Chłoniak płaszcza po co najmniej 1 poprzednim leczeniu
- •Transformacja Richtera (zmiana rodzaju chłoniaka) potwierdzona badaniem
- •Choroba nieodpowiadająca na leczenie lub powróciła po wcześniejszej terapii
- •Pacjent nie może lub nie chce przejść przeszczepu szpiku kostnego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (32)
University of Alabama at Birmingham
Birmingham, United States
Banner MD Anderson Cancer Center
Gilbert, United States
Mayo Clinic
Phoenix, United States
UC San Diego Health
La Jolla, United States
Stanford University
Stanford, United States
Colorado Blood Cancer Institute
Denver, United States
Yale University
New Haven, United States
Baptist Health Miami Cancer Institute
Miami, United States
Winship Cancer Institute of Emory University
Atlanta, United States
Georgia Cancer Center at Augusta University
Augusta, United States
Robert H Lurie Cancer Center
Chicago, United States
University of Kansas Cancer Center
Westwood, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, United States
Dana Farber Cancer Institute
Boston, United States
University of Michigan
Ann Arbor, United States
Mayo Clinic
Rochester, United States
Washington University, St. Louis
St Louis, United States
University of Nebraska Medical Center
Omaha, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Duke University Medical Center - Division of Hematologic Malignancies
Durham, United States
The Ohio State University Wexner Medical Center James Cancer
Columbus, United States
Oregon Health and Science University Knight Cancer Institute
Portland, United States
Allegheny Health Network Cancer Institute
Pittsburgh, United States
University of Pittsburgh - Hillman Cancer Center
Pittsburgh, United States
SCRI Oncology Partners
Nashville, United States
UT Southwestern Medical Center
Dallas, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Texas Transplant Institute
San Antonio, United States
Fred Hutchinson Cancer Center
Seattle, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, United States
University of Alberta Cross Cancer Institute
Edmonton, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Trial contact
Harshita Gahankari
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.